<DOC>
	<DOCNO>NCT01327079</DOCNO>
	<brief_summary>This propose investigation test follow hypothesis : 1 ) Enzymatic activity CYP2B6 characterize formation clearance methadone EDDP ( CLf , EDDP ) , directly relate gestational postnatal age ; 2 ) variation CYP2B6 gene ( SNPs ) associate variable activity CYP2B6 enzyme ( measure formation clearance , CLf , EDDP ) , 3 ) elimination rate methadone major metabolite EDDP neonates dependent glomerular filtration rate therefore stage development ( defined gestational postnatal age ) . The investigator propose develop PK model methadone dose neonate take account developmental stage genetic variability . The long-term goal propose investigation improve dose methadone neonate expose opioids utero post-natally , lead improve control withdrawal syndrome decrease adverse drug reaction associate current use methadone vulnerable patient . More immediately , investigator develop PK model methadone dose base relevant developmental genetic characteristic . The acquire knowledge base propose study lead efficacious treatment pain opiate withdrawal syndrome newborn infant decrease chance adverse drug reaction .</brief_summary>
	<brief_title>The Use Methadone Newborn Infants</brief_title>
	<detailed_description>The investigator identify recruit NICU CNMC 60 preterm neonate uniformly distribute respect gestational age encompass GA 's 22 le 43 week . - Stratified Selection Gestational Age ( GA ) : The study neonates select achieve balance follow GA stratum : ( 22-24 wks , 25-26 wks , 27-28 wks , 29-30 wks , 31-32 wks , 33-37 wks ; 38-43 wks ) . Stratification do ensure broad representation GA. As described , analyse treat GA continuous variable . - Randomization assign newborn infant group 1 ( n=30 ) group 2 ( n=30 ) . - Study medication : Methadone inulin administration Blood urine collect purpose research project . Blood drawn indwell arterial catheter already place clinical purpose . The amount blood obtain study related determination minimize keep less 3 mL/kg blood per 48 hour period . The study last 60 hour group 1 72 hour group . - DNA study 0.3ml whole blood collect subject - PK study Blood sample ( 0.2 mL per sample ) take 30 newborn infant t=0 , 1 , 4 , 12 , 36 , 60 h ( group 1 ) administration one dose methadone , 30 newborn infant t=0 , 2 , 8 , 24 , 48 , 72 hr ( group 2 ) administration methadone . A total 1.5 ml blood collect subject - Urine Collection Urine sample collect infant 's diaper ( wood pulp base study diaper ) every 3-4 hour first 24 hour period alternatively , indwell urinary catheter place base clinical indication unrelated study protocol .</detailed_description>
	<mesh_term>Critical Illness</mesh_term>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Morphine</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<criteria>Newborn infant gender race : postnatal age le 3 month indwell ( peripheral umbilical ) arterial line , already treat opioid ( morphine fentanyl ) clinical reason Neonates severe asphyxia grade III IV intraventricular hemorrhage , Neonates major congenital malformation facial malformation ( e.g. , cleave lip palate ) , neurological disorder Neonates receive continuous intermittent neuromuscular blocker neonate exclude : clinical biochemical evidence hepatic renal failure ( include systemic hypoperfusion receive drug CYP2B6 substrate expose utero methadone , despite fact indeed receive CYP2B6 substrate mother , exclude analyze subgroup</criteria>
	<gender>All</gender>
	<minimum_age>22 Weeks</minimum_age>
	<maximum_age>43 Weeks</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>NICU</keyword>
	<keyword>Methadone</keyword>
	<keyword>neonate</keyword>
</DOC>